Medicines for Europe marks 30 years of delivering more equitable access to off-patent medicines as it opens its annual European conference in Dublin, in partnership with Medicines for Ireland
With 1 in 5 individuals personally affected by medicines shortages in the last two years, Medicines for Ireland calls on the Department of Health and
Suppliers of generic, biosimilar, and value-added medicines call for reform of EU pharmaceutical laws to ensure equitable access to treatments for all patients Increased penetration
Suppliers of generic, biosimilar and value-added medicines unveil vision to enhance patient access and affordability, secure a resilient supply chain, and embed sustainable practices by 2029.
Negotiation on the new Framework Agreement on Supply and Pricing of Medicines set to be a key priority for incoming Medicines for Ireland chair and
Medicines for Ireland (MFI) are highlighting the role of inflation, rising energy and transport costs, and persistent global supply chain disruptions which have combined to create a
Medicines for Ireland (MFI) are urging Government to heed recent warnings from GPs and pharmacists nationwide on the growing risk of medicines shortages as inflation,
Medicines for Ireland (MFI) have highlighted the growing risk of medicines shortages as inflation, energy and transport costs continue to rise, and global supply chain
In line with today’s European Commission’s Guidelines on a European Gas Demand Reduction Plan1, Medicines for Europe urges Governments to maintain energy supply to medicines production sites in the event of energy restrictions in Europe.
According to findings commissioned by Medicines for Ireland (MFI) and compiled by IQVIA Ireland generic medicines now account for 57% of the volume of the total prescription market in Ireland.
We are committed to working with key stakeholders to affect real change and reforms that ensure Irish patients receive the best medical treatment in the most affordable way.
